Literature DB >> 6496920

[Long-term experiences with continuous peridural opiate analgesia with an implanted pump].

H Müller, K Aigner, I Worm, M Lobisch, A Brähler, G Hempelmann.   

Abstract

Continuous epidural opiate analgesia with an implantable, percutaneously refillable pump was induced in 6 patients with chronic pain of malignant origin. The efficacy of this method was compared with that of on-demand bolus-injections of epidural opiate. Side-effects and development of tolerance were not observed during a more than one year period of treatment. Increased daily doses for some days were only necessary in case of additional pain sources, e.g. induced by an intermediate operation. There were no hygienic problems (bacteriologic investigations) or problems due to technique of implantation (localisation of the implant, stability of the fixation, patency of the catheter). Examination of post mortem explanted pumps (determination of the flow rate, inspection for precipitation within the pump, testing of permeability of filters) and catheters (electron microscopy, testing of the material for surface conditions, tensile strength and elongation) as well as histological findings for local compatibility did not reveal adverse reactions after long-term treatment. Indications for this new method of pain treatment were established.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496920

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  3 in total

Review 1.  Patient-controlled spinal opiate analgesia in terminal cancer. Has its time really arrived?

Authors:  J Chrubasik; S Chrubasik; E Martin
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

2.  [The Huber needle as a special cannula for the puncture of implanted ports and pumps--a mistake in multiple variations].

Authors:  H Müller; J Zierski
Journal:  Klin Wochenschr       Date:  1988-10-03

3.  [Pain therapy with implanted medication pumps for chronic pain.].

Authors:  U Dell; D Covic; E Singer; M Fendrich
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.